European Society for Blood and Marrow Transplantation (EBMT), 2022


  1. How Long is Long-Enough? An Investigation into the Relationship between Trial Maturity and Uncertainty in Cost-Effectiveness, the Case of the First Commercially Available CAR-T Cell Therapy: Axicabtagene Ciloleucel
  2. Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy for Patients with Large B-Cell Lymphoma (LBCL) in the United States
  3. Patient‑Reported Outcomes in ZUMA‑7, a Phase 3, Randomized, Open‑Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi‑Cel) Versus Standard‑of‑Care Therapy in Relapsed / Refractory Large B‑Cell Lymphoma
  4. Primary Analysis of ZUMA‑7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard‑of‑Care (SOC) Therapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma
  5. Superiority of Axicabtagene Ciloleucel in Second‑Line Large B‑Cell Lymphoma in the Elderly
  6. Prophylactic Corticosteroid Use With Axicabtagene Ciloleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma: One‐Year Follow-Up of ZUMA-1 Cohort 6
  7. Primary Analysis of ZUMA‑12: A Phase 2 Study of Axicabtagene Ciloleucel as First‑Line Therapy in Patients With High‑Risk Large B‑Cell Lymphoma
  8. Long‑Term (5‑Year) Overall Survival in ZUMA‑1, the Pivotal Study of Axicabtagene Ciloleucel in Patients With Refractory Large B‑Cell Lymphoma
  9. Long-Term Follow-Up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma